NCT03236129View on ClinicalTrials.gov

Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells

PHASE3RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

February 22, 2018

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2026

Conditions
Hematological MalignanciesRegulatory T Cell DepletionRelapse
Interventions
PROCEDURE

T-reg depleted DLI

The patients in the experimental arm benefit of a DLI depleted from regulatory T lymphocytes

PROCEDURE

Standard DLI

The patients in this arm benefit of a standard DLI.

Trial Locations (1)

94010

RECRUITING

Henri Mondor Hospital, Créteil

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER